Redmile Group’s Nightstar Therapeutics NITE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
– Sell
-1,795,846
Closed -$20.7M – 88
2018
Q4
$20.7M Sell
1,795,846
-285,000
-14% -$3.8M 0.83% 40
2018
Q3
$42.5M Buy
2,080,846
+295,400
+17% +$6.06M 1.31% 26
2018
Q2
$28.6M Buy
1,785,446
+16,500
+0.9% +$235K 0.97% 36
2018
Q1
$25.4M Sell
1,768,946
-3,900
-0.2% -$53.2K 0.98% 32
2017
Q4
$21.9M Buy
1,772,846
+3,500
+0.2% +$62.9K 0.95% 38
2017
Q3
$28.8M Buy
+1,769,346
New +$38.2M 1.42% 26

Other funds holding NITE

Redmile Group's NITE Position: Q1 2019 in Review

Redmile Group sold out of Nightstar Therapeutics (NITE) in Q1 2019, closing a stake of 1,795,846 shares — an estimated $20.7M sold.

Redmile Group first reported a position in NITE in Q3 2017 and held it in 6 quarters. The position peaked at $42.5M in Q3 2018. 53 funds tracked by Wall St. Rank hold NITE as of Q1 2019.

  • Redmile Group reported no remaining Nightstar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Redmile Group sold 1,795,846 Nightstar Therapeutics shares in Q1 2019, an estimated $20.7M.
  • Redmile Group first reported a position in Nightstar Therapeutics in Q3 2017 and held it in 6 quarters.
  • Redmile Group's Nightstar Therapeutics position peaked at $42.5M in Q3 2018.
  • 53 funds tracked by Wall St. Rank held Nightstar Therapeutics as of Q1 2019.

Based on Redmile Group's 13F filing for Q1 2019, filed 15 May 2019.